Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 107

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 107
---
 and would expect to receive customary fees for the rendering of such services. In the ordinary course of its business, Leerink Partners has in the past held and may in the future hold positions, for its own account or the accounts of its customers, in equity, debt or other securities of Aadi, Kaken Parent or their respective affiliates. Consistent with applicable legal and regulatory requirements, Leerink Partners has adopted policies and procedures to establish and maintain the independence of its research department and personnel. As a result, - 67 -

Leerink Partners’ research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Aadi, Kaken Parent and the Divestiture and
other participants in the Divestiture that differ from the views of Leerink Partners’ investment banking personnel.

Aadi selected
Leerink Partners as its financial advisor in connection with the Divestiture based on Leerink Partners’ qualifications, reputation, experience and expertise in the biopharmaceutical industry, its knowledge of and involvement in recent
transactions in the biopharmaceutical industry and its familiarity with Aadi and its business. Leerink Partners is an internationally recognized investment banking firm that has substantial experience in transactions similar to the Divestiture.

In connection with Leerink Partners’ services as financial advisor to Aadi in the Divestiture, Aadi has agreed to pay Leerink Partners an aggregate fee
of $2.75 million, $1 million of which became payable upon the rendering by Leerink Partners of its opinion on December 19, 2024, and the remainder of which is payable contingent upon consummation of the Divestiture. In addition, Aadi has
agreed to reimburse certain of Leerink Partners’ expenses arising, and to indemnify Leerink Partners against certain liabilities that may arise, out of Leerink Partners’ engagement. The terms of the fee arrangement between Leerink Partners
and Aadi, which are customary in transactions of this nature, were negotiated at arm’s length between Leerink Partners and Aadi, and Aadi’s board of directors was aware of the arrangement, including the fact that a significant portion of
the fee payable to Leerink Partners is contingent upon the completion of the Divestiture.

Certain Unaudited Prospective Financial Information

Aadi does not, as a matter of course, develop or publicly disclose long-term projections as to future performance, revenues,
earnings or other results due to, among other reasons, the unpredictability and uncertainty of the underlying assumptions